Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Durvalumab Boosts Survival in Muscle-Invasive Bladder Cancer
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer significantly improved survival, reducing the risk for death by 25%, according to a preplanned interim analysis of the phase 3 NIAGARA trial. These results offer…
English